PMH30 COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN SETTING OF RISPERIDONE LONG-ACTING INJECTION FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA WHO ARE PARTIALLY ADHERENT TO THEIR MEDICATION
Nov 1, 2004, 00:00
10.1016/S1098-3015(10)66089-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)66089-5/fulltext
Title :
PMH30 COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN SETTING OF RISPERIDONE LONG-ACTING INJECTION FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA WHO ARE PARTIALLY ADHERENT TO THEIR MEDICATION
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66089-5&doi=10.1016/S1098-3015(10)66089-5
First page :
Section Title :
Open access? :
No
Section Order :
456